Literature DB >> 7533188

Patterns of cytokine secretion by autoreactive proteolipid protein-specific T cell clones during the course of multiple sclerosis.

J Correale1, W Gilmore, M McMillan, S Li, K McCarthy, T Le, L P Weiner.   

Abstract

To determine whether cytokine secretion patterns change with disease status in patients with multiple sclerosis (MS), we measured IFN-gamma, TNF-alpha beta, IL-4, IL-6, IL-10 and TGF-beta secretion in a panel of T cell clones (TCCs) specific for proteolipid protein (PLP) after stimulation with PLP peptides or polyclonal activators. During acute attack, the predominant pattern of cytokine secretion resembled that of murine Th1 cells; i.e, IFN-gamma and TNF-alpha beta, and appeared to be restricted to PLP-reactive TCCs. None of the TCCs isolated during acute attack produced TGF-beta in response to PLP, Con A, or anti-CD3 Ab. Half of these TCCs were, however, capable of TGF-beta secretion and mRNA expression upon stimulation with PMA and the calcium inonphore A23187, suggesting a possible defect in activation through the TCR/CD3 pathway. During remission in the same patients all but two PLP-TCCs showed patterns of cytokine secretion resembling that of murine Th0, Th1, and Th2 subsets. The levels of IL-10 secreted by these TCCs were significantly higher than those of TCCs isolated during acute attacks and those derived from normal subjects and patients with other noninflammatory neurologic diseases. Furthermore, 50% of these TCCs were capable of producing TGF-beta after Ag-specific or polyclonal stimulation. All TCCs isolated from control subjects exhibited a Th0 like secretion profile. These data indicate that different stages of disease in MS are characterized by different patterns of cytokine secretion by PLP-specific TCCs, suggesting a role for cytokines in clinical events during the course of MS.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7533188

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

Review 1.  The role of TNFalpha and lymphotoxin in demyelinating disease.

Authors:  C Lock; J Oksenberg; L Steinman
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  The neuroprotective agent SR 57746A abrogates experimental autoimmune encephalomyelitis and impairs associated blood-brain barrier disruption: implications for multiple sclerosis treatment.

Authors:  B Bourrié; E Bribes; M Esclangon; L Garcia; J Marchand; C Thomas; J P Maffrand; P Casellas
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

Review 3.  Regulation and function of class II major histocompatibility complex, CD40, and B7 expression in macrophages and microglia: Implications in neurological diseases.

Authors:  George M O'Keefe; Vince T Nguyen; Etty N Benveniste
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

4.  TGF-β signaling is altered in the peripheral blood of subjects with multiple sclerosis.

Authors:  Elise M Meoli; Unsong Oh; Christian W Grant; Steven Jacobson
Journal:  J Neuroimmunol       Date:  2010-11-19       Impact factor: 3.478

Review 5.  Stage-specific immune dysregulation in multiple sclerosis.

Authors:  Benjamin M Segal
Journal:  J Interferon Cytokine Res       Date:  2014-08       Impact factor: 2.607

6.  The method of deriving human T-cell clones alters the proportion of IL-10-producing cells.

Authors:  S B Cohen; L M Webb; M Feldmann
Journal:  Immunology       Date:  1996-03       Impact factor: 7.397

7.  Role of toll-like receptors in multiple sclerosis.

Authors:  Socorro Miranda-Hernandez; Alan G Baxter
Journal:  Am J Clin Exp Immunol       Date:  2013-02-27

8.  FOXP3, CBLB and ITCH gene expression and cytotoxic T lymphocyte antigen 4 expression on CD4(+) CD25(high) T cells in multiple sclerosis.

Authors:  F Sellebjerg; M Krakauer; M Khademi; T Olsson; P S Sørensen
Journal:  Clin Exp Immunol       Date:  2012-11       Impact factor: 4.330

9.  Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein.

Authors:  E A Elliott; H I McFarland; S H Nye; R Cofiell; T M Wilson; J A Wilkins; S P Squinto; L A Matis; J P Mueller
Journal:  J Clin Invest       Date:  1996-10-01       Impact factor: 14.808

Review 10.  Nuclear receptors and autoimmune disease: the potential of PPAR agonists to treat multiple sclerosis.

Authors:  Michael K Racke; Anne R Gocke; Mark Muir; Asim Diab; Paul D Drew; Amy E Lovett-Racke
Journal:  J Nutr       Date:  2006-03       Impact factor: 4.798

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.